IDO1 inhibition entered the clinic with a strong immunotherapy rationale, yet late-stage trials failed to improve outcomes. Explicyte and Institut Bergonié authors reviewed the tryptophan–kynurenine–AhR axis, from immune suppression and checkpoint resistance to the clinical performance of pathway-directed agents. The evidence points to incomplete intratumoral pharmacodynamics, context-dependent AhR biology, and weak biomarker selection—and supports broader strategies such as kynurenine depletion, dual IDO1/TDO2 blockade, and direct AhR modulation.
Explicyte scientists Jean-Philippe Guégan, Dominique Bodet, and Alban Bessede worked with medical oncologists from Institut Bergonié and the University of Bordeaux to examine why targeting tryptophan metabolism has not yet delivered the expected clinical benefit in cancer immunotherapy. Explicyte’s contribution covered methodology, evidence investigation, scientific drafting, conceptualization, review, and supervision. The review connects the immune biology of the tryptophan–kynurenine–aryl hydrocarbon receptor pathway with the performance of IDO1-directed clinical programs. It also evaluates alternative therapeutic entry points—including TDO2, extracellular kynurenine, and AhR—and defines the pharmacodynamic and biomarker strategies needed to test them more effectively.
The review followed the pathway from three rate-limiting enzymes—IDO1, IDO2, and TDO2—to kynurenine production and AhR activation. It connected tryptophan depletion with GCN2 activation and mTORC1 suppression in T cells, while kynurenine–AhR signaling was associated with PD-1 induction, regulatory T-cell differentiation, IL-10 production, CD39 expression, and tolerogenic myeloid states.
Across the clinical evidence reviewed, changes in circulating kynurenine did not consistently translate into antitumor activity. In a 52-patient phase I epacadostat monotherapy trial, doses of at least 100 mg twice daily produced an estimated 80–90% inhibition of IDO activity, yet no objective responses were reported and only 7 patients achieved stable disease—13.5% of the cohort.
ECHO-301/KEYNOTE-252 randomized 706 patients with unresectable or metastatic melanoma to epacadostat plus pembrolizumab or placebo plus pembrolizumab. Median progression-free survival was 4.7 versus 4.9 months (HR 1.00; P = 0.52), while overall survival was also not improved (HR 1.13; P = 0.81). The result exposed a major gap between systemic pharmacodynamic measurements and effective suppression of the pathway inside tumors.
The authors assessed approaches extending beyond selective IDO1 inhibition: engineered kynureninases that remove extracellular kynurenine, direct AhR antagonists, and dual IDO1/TDO2 inhibitors. At publication, phase I programs included BAY2416964 plus pembrolizumab with a planned enrollment of 78 patients and IK-175 with or without nivolumab with a planned enrollment of 93. Preclinical kynureninase studies also reported increased intratumoral CD8 T cells and stronger checkpoint-blockade activity than combinations using epacadostat.
Major IDO1 programs frequently measured circulating kynurenine without demonstrating sustained intratumoral pathway suppression. The review argues for stratifying patients through tumor IDO1 and TDO2 expression, local and systemic tryptophan-to-kynurenine measurements, downstream AhR activity, and pharmacodynamic endpoints that confirm target engagement within the tumor microenvironment.
The clinical failure of first-generation IDO1 inhibitors does not establish that tryptophan metabolism is therapeutically irrelevant. It shows that drug selection, tumor-level pharmacodynamics, pathway context, and patient enrichment must be addressed together.
Drug developers should distinguish movement in circulating biomarkers from target engagement inside the tumor and establish whether IDO1, TDO2, or downstream AhR signaling is dominant in the intended population. Translational teams need paired tissue and blood pharmacodynamics, pathway-based patient enrichment, and immune readouts to determine whether selective enzyme inhibition, kynurenine depletion, dual blockade, or AhR modulation is the most appropriate strategy.
